MS Speaks

Multiple Sclerosis => TREATMENTS => LEMTRADA (Campath, alemtuzumab) => Topic started by: agate on April 05, 2021, 03:17:30 pm

Title: Impact of previous DMT on effectiveness, safety outcomes in PwMS treated w/Lemtrada
Post by: agate on April 05, 2021, 03:17:30 pm

From the Journal of Neurology, Neurosurgery and Psychiatry (April 5,  2021), "Impact of previous disease-modifying treatment on effectiveness and safety outcomes, among patients with multiple sclerosis treated with alemtuzumab":




https://jnnp.bmj.com/content/early/2021/03/11/jnnp-2020-325304.long


A summary of the findings is in Multiple Sclerosis News Today (April 5)--"Moving from Gilenya to Lemtrada May Not Be Optimal Choice, Study Says":


https://multiplesclerosisnewstoday.com/news-posts/2021/03/17/impact-of-previous-disease-modifying-treatment-on-effectiveness-and-safety-outcomes-among-patients-with-multiple-sclerosis-treated-with-alemtuzumab/